The following is a summary of the Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript:
Financial Performance:
Total Q3 revenue was $71.7 million, a decrease from $84.7 million in the third quarter of 2023.
GAAP gross margin was 37.3%, with a non-GAAP gross margin of 40%.
Non-GAAP operating margin increased approximately 2 percentage points sequentially to minus 6%.Adjusted EBITDA income for Q3 was approximately $400,000, compared to an income of $18.1 million in Q3 2023.
Projected improvement in GAAP EPS loss from $1.95 to approximately $1.70 per share for the full year.
Business Progress:
Expanded carrier screening and hereditary cancer screening tests are in high demand.
Established a new $99 million contract over five years with VA hospitals for hereditary cancer and other germline tests.
Introduced KNOVA, a novel NIPT test, and received MoIDX approval for multiple hereditary cancer panels in the third quarter.
Opportunities:
Continued growth in core business areas: precision diagnostics, anatomic pathology, and pharma services.
The ability to further compete for biopharma service projects due to a larger test portfolio, including new platforms like 10x Genomics and Akoya.
Expanded presence in digital pathology, with 80% of slides digitized, enhancing operational efficiency and potential for integrating AI technologies in the future.
Risks:
Revenue from COVID-19 testing is now negligible, implying a pivot to more sustainable core business offerings.
A projected operating margin of approximately minus 12% for the year highlights operational risks tied to investments for growth.
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
